NP / PA
Aspirus Merrill Hospital & Clinics, INC
Aspirus Merrill Hospital & Clinics, INC was paid $11.12M by Medicaid between Jan 2018 and Dec 2024, across 106 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 18% of everything it billed.
33Billing provider infoASPIRUS MERRILL HOSPITAL & CLINICS, INC
MERRILL, WI 54452
MERRILL, WI 54452
33aNPI1124084678assigned 04/25/2006
33bProvider typeCertified Registered Nurse Anesthetist
28Total paid$11.12M
24GClaims188,401
24DCodes billed106
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Certified Registered Nurse Anesthetist providers in Wisconsin
Rank by total paid#1 of 15
Median peer was paid$5K
This provider vs. median2,151×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,817 | $1.55M | |
| 2019 | 26,833 | $1.41M | |
| 2020 | 22,138 | $1.28M | |
| 2021 | 26,993 | $1.42M | |
| 2022 | 28,216 | $1.61M | |
| 2023 | 30,627 | $1.97M | |
| 2024incomplete | 26,777 | $1.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 4,602 | 3,482 | $1.95M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 8,138 | 6,030 | $1.17M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.7% | 7,985 | 6,763 | $1.07M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 7,092 | 4,847 | $1.02M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.8% | 9,286 | 8,214 | $978K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 5,617 | 4,474 | $848K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.0% | 2,710 | 2,032 | $551K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.7% | 2,832 | 2,428 | $523K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 1,732 | 1,471 | $451K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,829 | 1,483 | $375K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 1,793 | 1,487 | $281K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.1% | 2,231 | 1,961 | $229K |
94 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.0% | 1,963 | $219K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.9% | 1,365 | $216K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 667 | $160K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 1,451 | $149K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 345 | $119K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,151 | $78K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,028 | $76K |
| 80053 | Comprehensive metabolic panel | <1% | 9,131 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,219 | $47K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,813 | $44K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 474 | $43K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,508 | $37K |
| 87070 | <1% | 3,318 | $31K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 741 | $28K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,042 | $27K |
| 84484 | <1% | 4,748 | $26K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 542 | $24K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 898 | $24K |
| 87430 | <1% | 1,630 | $24K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 82 | $17K |
| 83690 | <1% | 3,087 | $14K | |
| 83735 | <1% | 3,938 | $14K | |
| 81001 | <1% | 6,365 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,186 | $12K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 52 | $11K |
| 80306 | <1% | 911 | $10K | |
| 81025 | <1% | 1,123 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,794 | $9K |
| 83880 | <1% | 711 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 946 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 65 | $8K |
| 83605 | <1% | 1,634 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 768 | $8K |
| 86140 | <1% | 2,579 | $8K | |
| 85610 | <1% | 3,077 | $6K | |
| 87040 | <1% | 1,030 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 77 | $5K |
| 85379 | <1% | 898 | $5K | |
| 87077 | <1% | 972 | $5K | |
| 85730 | <1% | 1,870 | $5K | |
| 84703 | <1% | 761 | $5K | |
| 96368 | <1% | 26 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $3K |
| 84145 | <1% | 318 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,823 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,640 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 63 | $3K |
| 85027 | <1% | 904 | $3K | |
| 87420 | <1% | 146 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,744 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 191 | $2K |
| 82948 | <1% | 649 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,741 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 90 | $1K |
| G0378 | Hospital observation service, per hour | <1% | 14 | $1K |
| 87186 | <1% | 332 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,607 | $1K |
| 85007 | <1% | 967 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 20 | $1K |
| 82805 | <1% | 51 | $993.33 | |
| 87081 | <1% | 136 | $961.56 | |
| 87400 | <1% | 146 | $878.81 | |
| 87088 | <1% | 201 | $829.19 | |
| 85652 | <1% | 448 | $783.42 | |
| 82803 | <1% | 64 | $773.76 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,212 | $744.08 |
| 82150 | <1% | 141 | $651.13 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $537.38 |
| 73630 | <1% | 157 | $478.88 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,300 | $452.20 |
| 82550 | <1% | 68 | $261.89 | |
| 82728 | <1% | 16 | $152.24 | |
| 36000 | <1% | 271 | $113.27 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,194 | $91.76 |
| 81003 | <1% | 72 | $72.86 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,414 | $65.18 |
| 73610 | <1% | 29 | $53.52 | |
| 96376 | <1% | 762 | $50.21 | |
| 83615 | <1% | 14 | $44.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,760 | $42.21 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,774 | $35.33 |
| 81015 | <1% | 29 | $31.69 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 183 | $10.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 396 | $5.44 |
| A9270 | Non-covered item or service | <1% | 3,065 | $3.59 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 496 | $0.08 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 235 | $0.08 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 29 | $0.00 |
| 73130 | 0% | 13 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 443 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 704 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 17 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 14 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 438 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.